C12N 2740/16032
Use of virus as therapeutic agent, other than vaccine
Official title: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N2740/16032 (Use of virus as therapeutic agent, other than vaccine) appears on 19 US grants and 36 published applications in this corpus.
Search patents in C12N- Granted patents
- 19
- Published applications
- 36
- Assignees
- 14
- Inventors
- 64
- Latest grant
- 7 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 1 |
| 2014 | 1 | 2 |
| 2015 | 0 | 0 |
| 2016 | 0 | 2 |
| 2017 | 1 | 3 |
| 2018 | 2 | 3 |
| 2019 | 2 | 5 |
| 2020 | 3 | 3 |
| 2021 | 1 | 5 |
| 2022 | 2 | 2 |
| 2023 | 0 | 3 |
| 2024 | 2 | 2 |
| 2025 | 3 | 3 |
| 2026 | 2 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Vector genetically engineered with chimeric antigen receptor and against two or more targets and application thereof7 Jul 2026US 12,674,145 B2Sph Biotherapeutics (Shanghai) Limited.
- Nucleic acid molecules and dual-functional peptides having antiviral activity and delivery activity, compositions and methods thereof12 May 2026US 12,624,368 B2The University of Hong Kong
- Methods and compositions for the activation of gamma-delta T-cells2 Sep 2025US 12,403,155 B2American Gene Technologies International Inc.
- Antimicrobial compositions and methods of use thereof20 May 2025US 12,303,546 B2Morehouse School of Medicine
- Viral vectors and packaging cell lines4 Feb 2025US 12,215,337 B2Umoja Biopharma, Inc.
- Retroviral vectors8 Oct 2026US 2026/0308619 A1UCL Business PLC
- Viral vectors and packaging cell lines17 Apr 2025US 2025/0122532 A1Umoja Biopharma, Inc.
- Viral vectors and packaging cell lines17 Apr 2025US 2025/0122533 A1Umoja Biopharma, Inc.
- Compositions and methods for using purified human rna editing enzymes27 Mar 2025US 2025/0101427 A1The Regents of the University of California
- Gene sequence construct for gene therapy of human immunodeficiency virus infection24 Oct 2024US 2024/0352096 A1Kanglin Biotechnology (Hangzhou) Co., Ltd.
Most cited
By later US patents
- Methods and compositions for the activation of gamma-delta T-cells29US 10,137,144 B2American Gene Technologies International Inc. · 2018
- Methods and compositions for the activation of gamma-delta T-cells13US 10,420,789 B2American Gene Technologies International Inc. · 2019
- Methods and compositions for the activation of gamma-delta T-cells7US 10,772,905 B2American Gene Technologies International Inc. · 2020
- Antimicrobial compositions and methods of use thereof7US 8,669,226 B2Morehouse School of Medicine · 2014
- Antimicrobial compositions and methods of use thereof6US 9,556,224 B2Morehouse School of Medicine · 2017